Paper Details
- Home
- Paper Details
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
Author: GuYi, GuoLixia, LiKe, RenHongcan, SaiYang, SuWeiguo, WangJian, ZhangLi, ZhangWeihan
Original Abstract of the Article :
PURPOSE: This study evaluated the preclinical pharmacokinetics (PK) and disposition of fruquintinib (HMPL-013), a small molecule vascular endothelial growth factor receptors inhibitor. METHODS: In vitro and in vivo PK/ADME assays were conducted. Allometry and PK modeling/simulation were conducted t...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1007/s00280-014-2471-3
データ提供：米国国立医学図書館（NLM）
Fruquintinib: A Novel VEGFR Inhibitor with Promising Potential
This research examines the [preclinical pharmacokinetics and disposition] of fruquintinib (HMPL-013), a novel small molecule vascular endothelial growth factor receptors inhibitor. The study utilizes [in vitro and in vivo assays, allometry, and PK modeling/simulation] to assess fruquintinib's pharmacokinetic properties and predict its behavior in humans. The researchers found that fruquintinib has favorable preclinical pharmacokinetic properties, including high permeability, moderate oral bioavailability, and low clearance, suggesting a potential for successful clinical development. The study highlights the importance of preclinical research in guiding the development of novel therapeutic agents.
Navigating the Desert of Drug Development: A Promising New Agent
Developing new drugs is like navigating a vast and challenging desert, filled with potential pitfalls and uncertainties. This study explores the preclinical pharmacokinetic properties of fruquintinib, a novel VEGFR inhibitor, offering a promising oasis of potential for the treatment of various cancers. The findings suggest that fruquintinib possesses favorable pharmacokinetic characteristics, increasing its potential for successful clinical development and ultimately benefiting patients battling cancer.
Unlocking the Potential of Fruquintinib: A New Tool in the Fight Against Cancer
The study's findings offer a glimmer of hope for patients facing cancer. Fruquintinib, a novel VEGFR inhibitor, has shown promising preclinical pharmacokinetic properties, suggesting a potential for successful clinical development. This research provides valuable insights for navigating the complex terrain of drug development, offering a new tool in the fight against cancer and bringing hope for a brighter future for patients.
Dr.Camel's Conclusion
This research provides valuable insights into the preclinical pharmacokinetics and disposition of fruquintinib, a novel VEGFR inhibitor. The findings suggest that fruquintinib has favorable pharmacokinetic properties, making it a promising candidate for further clinical development and potentially offering a new therapeutic option for patients with various cancers.
Date :
- Date Completed 2014-09-26
- Date Revised 2022-07-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.